July 22, 2019Open Access

ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer

Key Points

Key points are not available for this paper at this time.

Abstract

Enzalutamide with ADT significantly reduced the risk of metastatic progression or death over time versus placebo plus ADT in men with mHSPC, including those with low-volume disease and/or prior docetaxel, with a safety analysis that seems consistent with the safety profile of enzalutamide in previous clinical trials in castration-resistant prostate cancer.

Bookmark

View Full Paper

Cite This Study

Armstrong et al. (Mon,) studied this question.

synapsesocial.com/papers/69d76c47db9d5e1bf4b8a532 https://doi.org/https://doi.org/10.1200/jco.19.00799

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Long-Term Antitumor Activity and Safety of Enzalutamide Monotherapy in Hormone Naïve Prostate Cancer: 3-Year Open Label Followup Results2017 · 26 citations
2The changing landscape in the management of newly diagnosed castration sensitive metastatic prostate cancer2020 · 5 citations
3Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer2018 · 1,043 citations
4Long-term Efficacy and Safety of Enzalutamide Monotherapy in Hormone-naïve Prostate Cancer: 1- and 2-Year Open-label Follow-up Results2015 · 46 citations
5Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study2016 · 283 citations

Bookmark

View Full Paper